Poxel was up on the Paris Bourse on Monday, after announcing that it had been granted a new patent in Japan for the treatment of type 2 diabetic patients with renal failure. The biopharmaceutical company said that the Japanese Patent Office had granted it a new patent covering the use of Twymeeg (imeglimine), its lead drug, in type 2 diabetic patients with moderate to severe renal failure until 2039. In a press release, the Lyon-based company points out that this new patent strengthens its portfolio in Japan, after having already obtained the same patent in China, the world's second-largest type 2 diabetes market. From its point of view, these developments reinforce ongoing discussions aimed at developing the commercialization of imeglimine beyond the Japanese market. On the Paris Bourse, Poxel shares gained over 7% on Monday afternoon in the wake of these announcements. In a reaction note, analysts at AllInvest Securities nonetheless point out that the company's financial situation remains "complicated". "At the time of its last cash flow communication, its financial visibility did not extend beyond the end of March 2025, and discussions had been initiated with its creditors to identify solutions", recalls the brokerage firm. The company's willingness to communicate on operational aspects seems to be aimed at reassuring the public that its activities will continue, but in the absence of refinancing solutions, the company's business could very quickly be in difficulty", explains AllInvest. Copyright (c) 2025 CercleFinance.com. All rights reserved.
